Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 16, 2018. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing details acquisitions of company securities resulting from dividend reinvestment plans.
Key Financial Metrics and Transaction Details
The filing does not report company-wide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. Instead, it provides specific transaction data for individual executives:
- Transaction Type: Acquisition of Ordinary Shares (GBP) and American Depositary Shares (ADSs) via dividend reinvestment.
- Transaction Date: January 11, 2018.
- Share Price (Ordinary Shares): GBP 13.306 per share.
- Share Price (ADSs): USD 36.84 per ADS.
- Exchanges: London Stock Exchange (XLON) and New York Stock Exchange (XNYS).
- Plan: 2009 Deferred Annual Bonus Plan.
Material Changes Versus Prior Period
The filing text does not provide comparative financial data or material changes in business operations versus prior periods. The document is strictly a regulatory disclosure of specific share acquisitions by named executives on a single date.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a factual record of compliance with reporting requirements for insider transactions.
Important Facts for Investor Verification
- Executive Participation: Multiple senior executives, including CEO Emma Walmsley and CFO Simon Dingemans, acquired shares through dividend reinvestment.
- Transaction Volume: Aggregated volumes varied by executive, with CFO Simon Dingemans acquiring the largest volume of Ordinary Shares (1,250.501 shares) and General Counsel David Troy acquiring the largest volume of ADSs (511.690 ADSs).
- Source of Funds: All transactions were funded by the reinvestment of dividends paid on January 11, 2018, rather than direct cash purchases by the executives.
- Instrument Types: Transactions involved both GBP-denominated Ordinary Shares (ISIN: GB0009252882) and USD-denominated ADSs (ISIN: US37733W1053).